Alnylam Pharmaceuticals (ALNY) EPS (Basic) Growth (3y) (2012 - 2026)
Powered by 
Analysis
Alnylam Pharmaceuticals (ALNY) EPS (Basic) Growth (3y) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 6.85% |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 11.71% |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | 86.03% |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | 18.44% |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 37.21% |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 36.73% |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | -38.31% |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 67.51% |
| 10 | Incyte | 25.59 Bn | 21.05 Bn | 1.57 Bn | 47.44% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 36.73% |
| Mar 31, 2026 | 45.89% |
| Dec 31, 2025 | 35.71% |
| Sep 30, 2025 | 38.73% |
| Jun 30, 2025 | 37.77% |
| Mar 31, 2025 | 58.69% |
| Dec 31, 2024 | 33.00% |
| Sep 30, 2024 | 20.34% |
| Jun 30, 2024 | 56.41% |
| Mar 31, 2024 | 32.65% |
| Dec 31, 2023 | 19.53% |
| Sep 30, 2023 | 36.45% |
| Jun 30, 2023 | -12.39% |
| Mar 31, 2023 | 4.61% |
| Dec 31, 2022 | 12.30% |
| Sep 30, 2022 | -20.09% |
| Jun 30, 2022 | -4.31% |
| Mar 31, 2022 | -4.97% |
| Dec 31, 2021 | -1.25% |
| Sep 30, 2021 | 10.99% |